Spotlight on Lung Fibrosis: Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity.
Pulmonary fibrosis is a progressive, typically fatal lung disease with few curative treatments. This study investigated the specific immune mechanisms that promote fibrosis and suggested a therapeutic approach that could be used alongside conventional anti-fibrotic drugs.
Fibrosis and COVID-19
Researchers have identified a unique COVID-19 signature in the lung, the mechanisms of which are contributors towards fibrosis.
Genome-wide identiﬁcation of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
Researchers have demonstrated differential methylation of promoters and enhancers between responders and non-responders prior to treatment with PD-1 inhibitors in a move that could improve outcomes for cancer treatment.
Fluorescence of Picrosirius Red Multiplexed with Immunohistochemistry for the Quantitative Assessment of Collagen in Tissue Sections
An emerging method of imaging offers a new opportunity to quantify collagen around areas of interest and an innovative approach to study the role of collagen in controlling cell behaviour.
Formaldehyde scavenging agents and the chemistry of antigen retrieval in FFPE tissues, and their potential for improved development of IHC staining protocols
A new approach to identify new and effective Antigen Retrieval reagents based on their ability to scavenge previously dissociated formaldehyde.
Measuring intratumoral vessel density using automated image analysis
Digital image analysis to analyse the intratumoral vessel density within specified regions of resected colon and TMA sections of colon tumour.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
To discover potential biomarkers of response and resistance to anti-PD1 monotherapy and combined anti-PD1/anti-CTLA-4 immunotherapies in a cohort of melanoma patients.
The role of immunohistochemistry in patient stratification and personalised medicine
Not all patients respond well to treatment and drugs have failed in the clinic due to “all patient” designs. Immunohistochemistry (IHC) could be used to group patients according to the expression levels of a specific biomarker. With successful validation and quantification, IHC assays can play a vital role in drug development as a method of patient stratification.